Eli Lilly price target lowered to $1,190 from $1,250 at Citi
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut
Eli Lilly has a long, proud history that begins ... This summer, Lilly is a sponsor of Team USA at the Olympics, and ...
The Motley Fool5d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...
Eli Lilly price target lowered to $970 from $1,000 at Wells Fargo
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
Hosted on MSN10mon
'Let's get serious': Eli Lilly slams Hollywood's Ozempic obsession ahead of Oscars
Eli Lilly is the company behind tirzepatide ... and this is why we made them,” he said in an exclusive interview with USA TODAY. "Let's get serious about what these medicines are for." ...
pharmaphorum1d
Lilly adds another sales channel for obesity drug Zepbound
Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy ... president of Lilly Cardiometabolic Health and Lilly USA. "Our goal is to break down barriers and provide ...
AOL15d
Has Eli Lilly Stock Peaked?
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...